Levonantradol Relieved One Morphine-Withdrawal Sign Without Suppressing the Syndrome in Monkeys
Levonantradol and nantradol alleviated abdominal contractions associated with morphine withdrawal in rhesus monkeys, but did not suppress the withdrawal syndrome overall. The same experiment also reported tolerance and negative findings in separate behavioral assays.
A symptom improvement was narrower than syndrome control
The cannabinoid-related compounds produced observable central nervous system depression. Neither suppressed morphine withdrawal, although both improved the chronic abdominal-contraction sign. Reporting only that improvement would overstate the result. Their directly observable effects were not antagonized by naloxone, further separating those observations from a simple claim of opioid-like action.
Tolerance and withdrawal were assessed separately
Repeated levonantradol administration produced marked tolerance to its own effects and cross-tolerance to nabilone and THC. Abrupt discontinuation did not produce observed withdrawal signs in the reported procedure. That null observation belongs to the tested regimen and observation method; it does not establish that every possible exposure lacks dependence potential.
Self-administration had its own comparator
When substituted for codeine in an intravenous self-administration procedure, neither compound maintained responding above vehicle rates. This was an operational animal test, not a human account of pleasure or craving. A negative result in that setup cannot establish a universal abuse-risk ranking for all cannabinoid compounds.
Interpreting the evidence
The study supports a selective withdrawal-sign finding alongside other positive and null outcomes. It does not establish human treatment efficacy or justify calling these experimental compounds equivalent to marijuana or opioid medicines.
Related reading: endogenous ligands administered as experimental drugs.
Research reference
Young AM; Katz JL; Woods JH (1981). Behavioral effects of levonantradol and nantradol in the rhesus monkey. Journal of clinical pharmacology. doi:10.1002/j.1552-4604.1981.tb02614.x. Evidence basis: study abstract.
